SCHEMBL4436345

SCHEMBL4436345

COc1ccc(C2(C(=O)CCl)CC2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
CYP3A4 P08684 1/20 0.46
CYP2C19 P33261 1/20 0.46
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
POLB P06746 1/20 0.45
TET3 O43151 1/20 0.45
FBXL19 Q6PCT2 1/20 0.45
CXXC5 Q7LFL8 1/20 0.45
TET1 Q8NFU7 1/20 0.45
KDM2B Q8NHM5 1/20 0.45
CXXC4 Q9H2H0 1/20 0.45
KDM2A Q9Y2K7 1/20 0.45
CACNA1G O43497 1/20 0.44
CACNA1H O95180 1/20 0.44
CACNA1I Q9P0X4 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MAPT P10636 1/20 0.44
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13545164 0.85 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2CYP3A4CYP2C19KMT2A
SCHEMBL838025 0.81 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2CYP3A4CYP2C19KMT2A
SCHEMBL4435186 0.80 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2CYP3A4CYP2C19KMT2A
SCHEMBL4445340 0.79 HSD11B1 (0.53) ALDH1A1SMN1; SMN2KMT2ATET3FBXL19
SCHEMBL301027 0.79 KMT2A (0.64) ALDH1A1SMN1; SMN2CYP3A4CYP2C19KMT2A
SCHEMBL12170296 0.79 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2CYP3A4CYP2C19KMT2A
SCHEMBL4437266 0.77 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2KMT2APOLBMAPT
SCHEMBL837139 0.77 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2CYP3A4CYP2C19KMT2A
SCHEMBL1480336 0.77 LMNA (0.55) ALDH1A1SMN1; SMN2CYP3A4CYP2C19KMT2A
SCHEMBL4435171 0.77 AKR1C1 (0.52) ALDH1A1SMN1; SMN2KMT2AMEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2134692-A2 QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION Wyeth a Corporation of the State of Delaware (US) 2009-12-23 EP disclosed
US-20080255192-A1 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins WYETH (US) 2008-10-16 US disclosed
WO-2008121817-A2 QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION WYETH (US) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255192-A1 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins VCAM1, ICAM1, SELE ALDH1A1 346/4885SMN1; SMN2 4234/4885CYP3A4 2973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.